iBio从AstralBio获得肥胖症治疗抗体IBIO-600,目的是在2026年进行临床试验。 iBio acquires obesity treatment antibody IBIO-600 from AstralBio, aiming for clinical trials in 2026.

iBio是一家生物制药公司,通过从AstralBio获得长效抗逆转录酶病毒抗体IBIO-600(IBIO-600)的权利,扩大了肥胖症和心血管治疗方案的范围。 iBio, a biopharmaceutical company, has expanded its obesity and cardiometabolic treatment program by acquiring rights to a long-acting anti-myostatin antibody, IBIO-600, from AstralBio. 抗体是为减少剂量而设计的,在临床预科研究中显示出有希望。 Designed for less frequent dosing, the antibody shows promise in preclinical studies. AstralBio提前收到750 000美元,可赚取最高2 800万美元的里程碑付款。 AstralBio received $750,000 upfront and could earn up to $28 million in milestone payments. iBio计划于2026年开始临床试验。 iBio plans to begin clinical trials in 2026.